Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

EXtended CriteriA Treatment for LIver Metastases and Heavy Tumour BURden (EXCALIBUR3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04840186
Recruitment Status : Recruiting
First Posted : April 9, 2021
Last Update Posted : April 14, 2021
Sponsor:
Information provided by (Responsible Party):
John Christian Fischer Glent, Oslo University Hospital

Brief Summary:
Patients with multiple colorectal liver metastases that progress on 1st line chemotherapy have a very dismal prognosis, and their options are few. Resections are regularly performed although this is only supported by anecdotal evidence for this patient group. We want to assess whether resections actually confer benefit as compared to 2nd line chemotherapy alone, in a randomized controlled trial.

Condition or disease Intervention/treatment Phase
Liver Metastases Colorectal Cancer Procedure: Liver-resection or ablation Drug: 2nd line chemotherapy Not Applicable

Detailed Description:

Colorectal cancer (CRC) is the second most frequent malignant disease in Norway (Cancer in Norway 2017). About 50% of the patients will have metastatic disease at the time of diagnosis or develop metastatic disease later on. Liver metastases are the most frequent presentation of metastatic disease. Liver resection is considered the only curative treatment option in CRC patients with liver metastases, however only about 20% of the patients are candidates for liver resection. The treatment option for the majority of the patients is palliative chemotherapy with a median overall survival from start of chemotherapy of about 2 years, and only 10-12 months from starting 2nd line chemotherapy.

While high-quality data (randomized trials) is wanting, it is generally accepted that the only curative treatment for colorectal liver metastases (CRLM) is surgery. Liver resections are generally well tolerated and safe 1, but some patients recur early and probably have no benefit from surgery, or even a net loss of quality-of-life (QoL). These are hard to identify beforehand, but patients with multiple tumours that progress on 1st line chemotherapy are at high risk of early recurrence following resection2, 3. These patients are in a grey zone: their metastases may be technically resectable, but the aggressive biology of their disease makes overall outcome of surgery highly uncertain. The decision to offer resection to some of these patients primarily results from want of better alternatives and from lack of sufficiently precise prognostication.

As resections are generally well tolerated and adequate prognostication is wanting, there is a tendency to offer resections to patients who have borderline resectable CRLM or who exhibit other non-favourable traits like large or multiple metastases, or progression on 1st line chemotherapy. Resections followed by early recurrence represent a net loss of quality-of-life and an unwanted expenditure for society. Exploring the optimal treatment modality for patients in this grey zone, i.e. with uncertain benefit from surgery, is important to provide optimal treatment for patients in a critical situation.

Palliative chemotherapy is in general the only treatment option for the vast majority of non-resectable patients. The expected median overall survival (OS) from start of first line chemotherapy is about 2 years and the 5 years OS is about 10%, although longer median OS has been obtained in selected patients with good performance status (ECOG 0-1), no (K)RAS or BRAF mutations and left-sided tumours 4-8. The OS from start of second line chemotherapy however is only 10-12 months 9. This places the prognosis for this group of cancer patients on par with those having pancreatic cancer.

This trial targets a group of patients that are not eligible for the Excalibur 1 and 2 trials but still have as dismal or even worse prognosis. They will - according to the inclusion criteria - have a large tumour burden and have shown progression on 1st line systemic chemotherapy treatment. Based on previous trials, only 30 % of this patient group are estimated to be alive after two years. These patients have today only one treatment modality available: 2nd line systemic chemotherapy. Response can, however, only be expected in a small minority.

With such a dismal outcome for these patients, almost any attempt to improve survival would be warranted and anecdotal evidence shows that some appear to benefit substantially. This may, however, be a result of biased selection and the benefit of surgery in this grey zone is unproven.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: RCT with two parallell arms. One with second line chemotherapy and the other with second line chemotherapy + resection
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: EXtended CriteriA Treatment for LIver Metastases and Heavy Tumour BURden
Actual Study Start Date : March 23, 2021
Estimated Primary Completion Date : March 23, 2024
Estimated Study Completion Date : March 2026

Arm Intervention/treatment
Active Comparator: 2nd line chhemotherapy
Patients in this arm will be receiving the standard care which is 2nd line chemotherapy. Type of chemotherapy determined by treating oncologist.
Drug: 2nd line chemotherapy
2nd line chemotherapy. Type of chemotherapy is determined by treating oncologist

Active Comparator: 2nd line chemotherapy + resection
Patients in this arm will be treated with liver resection and/or ablation at Oslo University Hospital followed by adjuvant 2nd line chemotherapy. Type of chemotherapy is determined by treating oncologist.
Procedure: Liver-resection or ablation
Liver-resection of colorectal liver metastasis. Ablation can be used as adjunct to surgery.

Drug: 2nd line chemotherapy
2nd line chemotherapy. Type of chemotherapy is determined by treating oncologist




Primary Outcome Measures :
  1. Median survival [ Time Frame: 2years ]
    Primary endpoint is median survival after two years to see if the survival is different in the two groups.


Secondary Outcome Measures :
  1. Quality of Life [ Time Frame: EQ-5D-5L will be obtained at inclusion, week 6,12,18,24,36,48,60,72,84,96,108. ]
    Quality of life will analyzed by EuroQoL Group questionaire EQ-5D-5L

  2. Progression free survival PFS [ Time Frame: From inclusion to sign of progresion, tentatively less than 14months. ]
    Time from inclusion to sign of progression defined by the RECIST-criteria

  3. Quality of life [ Time Frame: EORTC QLQ-C30 will be obtained at inclusion, week 6,12,18,24,36,48,60,72,84,96,108. ]
    Quality of life will be analyzed by EORTC QLQ-C30



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Verified adenocarcinoma in colon or rectum
  2. Liver metastases that are technically resectable (ablation can be used as an adjunct) without PVE, HVE or ALPPS, but judged in need of further (next line) chemotherapy based on insufficient response to at least one line of chemotherapy. And either

    a. Six or more liver metastases, with extra-hepatic disease i. def: >3 pulmonary metastases/radiologically positive non-liver hilar lymph nodes. Or b. Ten or more liver metastases with at least one of the following negative prognostic signs: i. At least one lesion > 7 cm in diameter before chemotherapy ii. CEA > 100 following a full cycle of chemotherapy)?? iii. KRAS and/or BRAF mutant primary tumour. iv. Node positive primary tumour. Or c. Fifteen or more liver metastases

  3. ECOG 0/2
  4. Informed consent

Exclusion Criteria:

Any of the following criteria will exclude participation in the trial:

  1. New liver metastases emerging during completed chemotherapy.

    a. These patients may be included if they undergo a complete cycle of next line chemotherapy without new liver metastases emerging.

  2. Previous or current bone or CNS metastatic disease
  3. Any other reason why, in the opinion of the investigators, the patient should not participate.

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04840186


Contacts
Layout table for location contacts
Contact: John Christian F Glent, MD 92214992 ext 0047 uxgloh@ous-hf.no

Locations
Layout table for location information
Norway
Oslo University Hospital Recruiting
Oslo, Norway, 0372
Contact: Victoria L Bringsjord, RN    23073303 ext 0047    vicbri@ous-hf.no   
Sponsors and Collaborators
Oslo University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Kristoffer Lassen, MD PhD Oslo University Hospital
Layout table for additonal information
Responsible Party: John Christian Fischer Glent, Principal Investigator, Oslo University Hospital
ClinicalTrials.gov Identifier: NCT04840186    
Other Study ID Numbers: 167434
First Posted: April 9, 2021    Key Record Dates
Last Update Posted: April 14, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Neoplastic Processes
Pathologic Processes
Liver Diseases